NCT06099769 - A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer | Biotech Hunter

Enrollment

201

Participants

Timeline

Start Date

October 18, 2023

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions

Metastatic Breast Cancer

Interventions

DRUG

Enzalutamide

mouth once daily (160 mg/day)

DRUG

Mifepristone

mouth once daily 300-mg tablet

DRUG

TPC

"The treating physician must select from one of the following regimens:~* Eribulin 1.4 mg/m2 IV Day 1 and Day 8 in a 21-day cycle~* Capecitabine 1000-1250 mg/m2 twice daily, orally Day 1-14 in a 21-day cycle~* Paclitaxel 80 mg/m2 IV Day 1, Day 8 in a 21-day cycle~* Carboplatin AUC 6 IV Day 1 in a 21-day cycle~* Carboplatin AUC 2 IV Day 1, Day 8 and Day 15 in a 21-day cycle"

Trial Locations (12)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack

27514

RECRUITING

University of North Carolina, Chapel Hill

35294

RECRUITING

University of Alabama at Birmingham, Birmingham

60637

RECRUITING

University of Chicago Medical Center, Chicago

94143

RECRUITING

University of California San Francisco (Data collection only), San Francisco

02115

RECRUITING

Dana Farber Cancer Institute (Data Collection Only), Boston

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale